Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Interim Management Statement

15 May 2008 07:00

Embargoed Release: 07.00hrs Thursday 15 May 2008

SOPHEON PLC ("Sopheon" or the "Company") INTERIM MANAGEMENT STATEMENT

Sopheon plc, the international provider of software and services that improve the financial return from innovation and product development investments, issues its first interim management statement for the period since 1 January 2008 to the date of this announcement, in line with the requirements of the EU Transparency Directive.

As expected we had a productive first quarter this year, recording revenues 58% higher than in the first quarter of 2007, itself a relatively strong quarter by historic standards. Since the end of 2007 we have closed a total of 13 license orders and extensions, taking our total licensee base to 145. Our consultancy business continued to add new projects both in conjunction with new license orders, and through additional sales to existing customers. Our recurring revenue base has also continued to grow, amounting to over ‚£2.8 million, up from ‚£1.8 million in May last year. As in the past, our reported results in a particular period will be affected by the timing and size of individual sales; however this continues to be offset by increasing levels of repeat business from our growing client base. We are also encouraged that revenue visibility for the full year from contracted business and recurring revenue streams now stands at ‚£5 million compared to full year revenues last year of ‚£6.3 million; meanwhile we continue to work a full sales funnel with additional sales closures expected in the current quarter.

In March we launched the most significant new release of our Accolade software solution since it was introduced to the market more than six years ago. Many of the enhancements offered in this latest version of the software are based on our work with existing customers such as General Motors and Electrolux. These new capabilities position Accolade to move beyond the process manufacturing markets that we have historically targeted and into the large aerospace, defense and automobile sectors. The combination of Accolade and Vision Strategist, the product that came to us through the acquisition of Alignent Software, constitutes the first solution set in the industry to integrate strategic product planning and product development execution. Underlining this advance, AMR Research recently identified Sopheon as the most mature product portfolio management offering in the market today.

Our product advances have been matched by investment in new recruits that bring experience in the new markets we are pursuing. That said, we very much understand the global economic situation continues to remain uncertain, and we weigh each investment decision carefully. We are confident we are making the right choices, and remain positive about the outlook for the coming year.

For further information contact:

Barry Mence, Chairman Sopheon plc + 44 (0) 1483 685 735 Arif Karimjee, CFO Vikki Krause Hansard Communications + 44 (0) 207 245 1100 + 44 (0) 7515 922906 Claire Verhagen Citigate First Financial + 31 (0) 205 754 010 David Newton Seymour Pierce + 44 (0) 207 107 8000 About Sopheon

Sopheon is an international provider of software and services that help organizations improve the business impact of product innovation. Sopheon's solutions automate and govern the innovation process, enabling companies to increase revenue and profits from new products. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in the Netherlands. For more information, please visit www.sopheon.com.

vendor
Date   Source Headline
24th Jul 20199:05 amRNSSecond Price Monitoring Extn
24th Jul 20199:00 amRNSPrice Monitoring Extension
24th Jul 20197:00 amRNSTrading Update
13th Jun 20191:06 pmRNSResult of AGM
13th Jun 20197:00 amRNSAccolade 12.3
13th Jun 20197:00 amRNSAGM Statement
11th Jun 20191:32 pmRNSIssue of Equity
15th May 20197:00 amRNSSopheon Expands Customer Foothold in Asia
13th May 20199:14 amRNSIssue of Equity
28th Mar 20197:00 amRNSSopheon and National Foods Limited Partnership
21st Mar 20197:00 amRNSFinal Results
5th Feb 20197:00 amRNSIssue of Equity
29th Jan 20197:00 amRNSTrading Update
24th Jan 20194:41 pmRNSSecond Price Monitoring Extn
24th Jan 20194:35 pmRNSPrice Monitoring Extension
17th Jan 20197:00 amRNSAccolade Release 12.2
11th Jan 20197:00 amRNSTrading Update
8th Jan 20197:00 amRNSSopheon Partners with The Hershey Company
18th Dec 20182:53 pmRNSIssue of Equity
16th Nov 201812:54 pmRNSIssue of Equity
31st Oct 20185:18 pmRNSIssue of Equity
23rd Oct 20187:00 amRNSSopheon Awarded The Nature's Bounty Co. Business
8th Oct 20189:05 amRNSSecond Price Monitoring Extn
8th Oct 20189:00 amRNSPrice Monitoring Extension
8th Oct 20187:00 amRNSTrading Update
10th Sep 20187:00 amRNSDoosan Bobcat Awards Sopheon Innovation Contract
7th Sep 20185:48 pmRNSIssue of Equity
29th Aug 20183:54 pmRNSIssue of Equity & Holdings in Company
28th Aug 20187:00 amRNSAccolade Enterprise Innovation Management
23rd Aug 20187:00 amRNSHalf Yearly Report
19th Jul 201811:05 amRNSSecond Price Monitoring Extn
19th Jul 201811:00 amRNSPrice Monitoring Extension
19th Jul 20187:00 amRNSTrading Update
5th Jul 20189:40 amRNSGrant of Options / PDMR Dealing
3rd Jul 20189:24 amRNSIssue of Equity
13th Jun 20182:37 pmRNSIssue of Equity
7th Jun 201812:09 pmRNSResult of AGM
7th Jun 20187:00 amRNSAGM Statement
31st May 20182:56 pmRNSIssue of Equity
17th May 20188:01 amRNSResult of Secondary Placing
16th May 20183:05 pmRNSProposed Secondary Placing
15th May 20187:00 amRNSIssue of Equity
27th Apr 20183:59 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAccolade Release 12.0
23rd Mar 20183:56 pmRNSIssue of Equity
23rd Mar 20187:00 amRNSIssue of Equity
22nd Mar 20187:00 amRNSFinal Results
20th Feb 20187:00 amRNSSopheon named in Annual Reader's Choice List
12th Feb 20189:24 amRNSGrant of Options / PDMR dealing
5th Feb 20183:35 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.